The FDA announced the start of two real-time clinical trials by AstraZeneca and Amgen, marking a shift toward faster drug development by reporting trial data and safety signals as they occur. This initiative aims to reduce delays in regulatory decisions by allowing the FDA to monitor trials continuously rather than after phases conclude. The agency also issued a Request for Information to design a broader pilot program launching this summer, seeking public input to refine the approach. This move could transform clinical trials by enabling continuous data flow and quicker access to promising treatments.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
